0001062993-24-014792.txt : 20240809
0001062993-24-014792.hdr.sgml : 20240809
20240809172447
ACCESSION NUMBER: 0001062993-24-014792
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230808
FILED AS OF DATE: 20240809
DATE AS OF CHANGE: 20240809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rottinghaus Scott T.
CENTRAL INDEX KEY: 0001942407
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 241194102
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-08-08
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001942407
Rottinghaus Scott T.
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-08-08
4
F
0
1467
17.23
D
25533
D
Common Stock
2024-08-08
4
F
0
1466
12.73
D
18784
D
Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on August 8, 2022.
Such amount excludes securities acquired or disposed of subsequent to August 8, 2023.
Exhibit 24 Power of Attorney filed herewith.
/s/ Matthew Kowalsky as attorney-in-fact
2024-08-09
EX-24.1
2
exhibit24-1.txt
S. ROTTINGHAUS POA
POWER OF ATTORNEY
Know all by these presents that the undersigned hereby constitutes and appoints
each of Jay R. Luly, Paul J. Mellett, Matthew P. Kowalsky, Stacie Aarestad
and Ryan Rourke Reed, or each of them acting individually, the undersigned's
true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned a Form ID application to
be filed with the Securities and Exchange Commission to obtain EDGAR codes for
the undersigned;
(2) execute for and on behalf of the undersigned Forms 3, 4, and 5 with respect
to the securities of Enanta Pharmaceuticals, Inc. (the "Company") in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID
application or Form 3, 4, or 5, complete and execute any amendment or
amendments thereto, and timely file such forms with the United States
Securities and Exchange Commission and any stock exchange or similar
authority; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934, as amended.
This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned's holdings of and transactions in securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 8th day of August, 2024.
By: /s/ Scott Rottinghaus
Print Name: Scott T. Rottinghaus, M.D.
(Signature page to Section 16 Power of Attorney for Enanta)